OPAC (Online Public Access Catalog)
Pencarian Koleksi UPA Perpustakaan
start it by typing one or more keywords for title, author or subject
Intravenous infusion for the controlled exposure to the dual ABCB1 and ABCG2 inhibitor elacridar in nonhuman primates
Sébastien Goutal - Personal Name
Oliver Langer - Personal Name
Sylvain Auvity - Personal Name
Elacridar (GF120918) is a highly potent inhibitor of both P-glycoprotein (ABCB1) and breast cancer resistance protein
(ABCG2), the main efflux transporters expressed at the blood-brain barrier (BBB). Elacridar shows very low aqueous solubility,
which complicates its formulation for i.v. administration. An intravenous infusion protocol would be preferred to achieve high
and controlled plasma concentrations of elacridar in large animals, including nonhuman primates. Formulation of elacridar for i.v.
infusion was achieved using a co-solvent strategy, resulting in an aqueous dispersion with a final concentration of 5 g L−1
elacridar with tetrahydrofuran (5% w/v) in aqueous D-glucose solution (2.5%, w/v). Particle size (mean = 2.8 ± 0.9 μm) remained
stable for 150 min. The preparation was i.v. administered as a continuous infusion (12 mg kg−1 h−1 for 90 min) to three baboons.
Arterial and venous plasma pharmacokinetics (PK) of elacridar were monitored using a newly developed and validated HPLCUV method. Elacridar concentration increased rapidly to reach a plateau at 9.5 μg mL−1 within 20 min after the start of infusion.
Elacridar PK in venous plasma did not differ from arterial plasma facing the BBB, indicating the absence of an arteriovenous
concentration gradient. Intravenous infusion of elacridar allows for controlled exposure of the BBB and offers a useful tool to
assess the impact of ABCB1/ABCG2 on drug disposition to the brain in nonhuman primates, a relevant animal model for the
study of transporter function at the BBB.
(ABCG2), the main efflux transporters expressed at the blood-brain barrier (BBB). Elacridar shows very low aqueous solubility,
which complicates its formulation for i.v. administration. An intravenous infusion protocol would be preferred to achieve high
and controlled plasma concentrations of elacridar in large animals, including nonhuman primates. Formulation of elacridar for i.v.
infusion was achieved using a co-solvent strategy, resulting in an aqueous dispersion with a final concentration of 5 g L−1
elacridar with tetrahydrofuran (5% w/v) in aqueous D-glucose solution (2.5%, w/v). Particle size (mean = 2.8 ± 0.9 μm) remained
stable for 150 min. The preparation was i.v. administered as a continuous infusion (12 mg kg−1 h−1 for 90 min) to three baboons.
Arterial and venous plasma pharmacokinetics (PK) of elacridar were monitored using a newly developed and validated HPLCUV method. Elacridar concentration increased rapidly to reach a plateau at 9.5 μg mL−1 within 20 min after the start of infusion.
Elacridar PK in venous plasma did not differ from arterial plasma facing the BBB, indicating the absence of an arteriovenous
concentration gradient. Intravenous infusion of elacridar allows for controlled exposure of the BBB and offers a useful tool to
assess the impact of ABCB1/ABCG2 on drug disposition to the brain in nonhuman primates, a relevant animal model for the
study of transporter function at the BBB.
Availability
| EB00000002765K | Available |
Detail Information
Series Title
-
Call Number
-
Publisher
: ,
Collation
-
Language
ISBN/ISSN
-
Classification
NONE
Detail Information
Content Type
E-Jurnal
Media Type
-
Carrier Type
-
Edition
-
Subject(s)
ATP-binding cassette
BCRP
Blood-brain barrier
Breast cancer resistance protein
Multidrug resistance
P-glycoprotein
Specific Detail Info
-
Statement of Responsibility
-
No other version available
File Attachment
